Biosimilar Tentative Approvals Could Flow From US Supreme Court Case

If high court decides that biosimilar sponsors must wait until licensure before providing 180-day notice of commercial launch, FDA may face pressure to start granting tentative licenses for 351(k) applications, industry lawyer says.